

# Update zur systemischen Therapie des metastasierten Nierenzellkarzinoms – ASCO 2023

*Manfred Johannsen, Robert Schönfelder, Jörg Klier, Rolf Eichenauer, Frank König, Jörg Schröder, Elke Hempel, Christian Doehn*

## Literatur

1. Motzer RJ et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer* 2022; 128(11): 2085–97
2. Rini B et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. *J Clin Oncol* 2023; 41(suppl 17; abstr LBA4501)
3. Burotto M et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. *J Clin Oncol* 2023; 41(suppl 6; abstr 603)
4. Motzer RJ et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). *J Clin Oncol* 2023; 41(suppl 16; abstr 4502)
5. Heng D et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol* 2013; 14(2): 102–3
6. Choueiri TK et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal Cell Carcinoma. *N Engl J Med* 2023; 388(19): 1767–78
7. Choueiri T et al. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. *J Clin Oncol* 2023; 41(suppl 17; abstr LBA4500)
8. Ciccarese C et al. Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis. *Eur Urol* 2023; 83(2): e45–e46

9. Johannsen M et al. Erstlinientherapie des metastasierten Nierenzellkarzinoms – Update 2023. *Journal Onkologie* 2023; 3: 54–8
10. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. Version 4.0 – Februar 2023. AWMF-Registernummer: 043-017OL. ([https://www.leitlinienprogramm-onkologie.de/fileadmin/user\\_upload/Downloads/Leitlinien/Nierenzellkarzinom/Version\\_4/LL\\_Nierenzellkarzinom\\_Langversion\\_4.0.pdf](https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Nierenzellkarzinom/Version_4/LL_Nierenzellkarzinom_Langversion_4.0.pdf)). Zugegriffen: 26.06.2023
11. Motzer RJ et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade, *Cancer Cell*. 2020 Dec 14; 38(6): 803–817.e4.
12. Albiges L. The Case for Doublet Therapy. ASCO 2023
13. Burotto M et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. *J Clin Oncol* 2023; 41: (suppl 6; abstr 603)